Avelumab and Merkel Cell Carcinoma: Understanding the Evidence

From General Health Science to Occupational Exposure Concerns

The legacy of general health and science communication has long emphasized broad public wellness principles, disease prevention, and the interpretation of emerging biomedical research for lay audiences. Within this tradition, discussions of pharmaceutical interventions typically focus on therapeutic benefits and standard risk-benefit profiles, framed in accessible language that avoids specialized mechanistic detail. This heritage provides a foundation for understanding how medical knowledge evolves from clinical trials to public awareness. Transitioning from this general context to a specific occupational exposure concern requires a shift in focus. In mass production environments, workers may encounter pharmaceutical compounds during manufacturing, handling, or quality control processes. One such compound is Avelumab, a monoclonal antibody used in oncology. While clinical studies have established its efficacy in treating certain cancers, including Merkel cell carcinoma, occupational exposure scenarios raise distinct considerations. The risk profile for workers who may come into contact with Avelumab during production differs from that of patients receiving therapeutic doses. Studies examining Avelumab exposure and Merkel cell carcinoma risk in occupational settings focus on potential unintended consequences of chronic low-level contact, rather than prescribed medical use. This pivot from general health information to occupational exposure concern underscores the need for targeted risk assessment in manufacturing environments, where exposure parameters and health outcomes require separate evaluation from clinical contexts.

Avelumab as a Therapeutic Agent for Merkel Cell Carcinoma

Avelumab, a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1), functions as an immune checkpoint inhibitor and is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC) (https://pubmed.ncbi.nlm.nih.gov/29799096/). MCC is a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis, and avelumab was the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). MCC is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit for advanced MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/).

Causation and Risk: Avelumab as Treatment, Not Cause

Regarding causation, avelumab is not a cause of MCC but rather a treatment for it. The evidence indicates that avelumab is used to treat metastatic MCC, and its pharmacology as a PD-L1 inhibitor is intended to enhance the immune response against cancer cells. The risk narrative centers on the adequacy of warnings about avelumab's efficacy and adverse effects in the context of MCC. The evidence shows that for patients who are refractory to avelumab, treatment options are limited, and combined ipilimumab plus nivolumab has been studied as a subsequent therapy. In a retrospective study of five patients at three German academic sites, three out of five patients with avelumab-refractory metastatic MCC responded to combined ipilimumab plus nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG also investigated ipilimumab plus nivolumab in avelumab-refractory MCC, noting that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC highlighted that despite advances, about 50% of patients progress on immune checkpoint inhibitor therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). The timeline between exposure to avelumab and documented harm is not directly addressed in the provided evidence, but the evidence does indicate that patients may develop immune-related adverse events during treatment. The mechanistic pathways linking avelumab to MCC are not about causation of the disease but about the drug's mechanism of action in treating it. Avelumab functions as an immune checkpoint inhibitor by blocking PD-L1, which can enhance T-cell responses against MCC cells. The evidence discusses T-cell responses in MCC and implications for improved immune checkpoint blockade, noting that standard treatment of metastatic MCC involves anti-PD-1/-PD-L1 inhibitors like avelumab (https://pubmed.ncbi.nlm.nih.gov/34445385/). Causation-related considerations for affected patients should focus on the fact that avelumab is a treatment for MCC, not a cause. The adequacy of warnings regarding avelumab and MCC is supported by clinical trial data showing efficacy in a subset of patients, but also acknowledging that a significant proportion do not respond or experience adverse events. The evidence does not suggest that avelumab induces MCC; rather, it is a therapeutic agent for an existing condition. The risk for patients lies in the potential for lack of response or progression on therapy, as well as immune-related adverse events, which are common with immune checkpoint inhibitors. In summary, the evidence supports that avelumab is an approved treatment for metastatic MCC with demonstrated efficacy in some patients, but with a notable proportion of non-responders and those who progress. The risk narrative should emphasize that avelumab is not a causative agent for MCC but a therapeutic intervention, and warnings should address the potential for treatment failure and adverse effects.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Is avelumab known to cause Merkel cell carcinoma?

No, avelumab is not a cause of Merkel cell carcinoma. It is an immune checkpoint inhibitor approved for the treatment of metastatic Merkel cell carcinoma. The evidence indicates that avelumab is used to treat MCC, not induce it. The risk for patients lies in potential lack of response or immune-related adverse events, not causation of the disease.

What does the evidence say about avelumab and Merkel cell carcinoma risk?

The evidence shows that avelumab is effective in about one-third of patients with chemotherapy-refractory metastatic MCC, but approximately 50% of patients do not respond or progress on therapy. Immune-related adverse events are common. The risk narrative focuses on treatment efficacy and adverse effects, not on avelumab causing MCC.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.